tirzepatide removed from fda shortage list Eli Lilly's weight loss drugs the FDA's GLP-1 No Longer on FDA's

Current blockbuster obesity drugs typically require weekly injections

December 2025: IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (MDL Number 3163) is now active

In the evolving landscape of weight management, peptide therapy has emerged as a groundbreaking approach, particularly through the use of weight loss injections

Semaglutide: active ingredient in Ozempic and Wegovy Ozempic : This form of semaglutide is primarily prescribed for Type 2 Diabetes management

doi:10.1016/S0140-6736(18)32260-8 Iepsen EW, Torekov SS, Holst JJ